BiotechTube

4D-150 IVT + Aflibercept IVT

Phase 1/2Recruiting
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neovascular (Wet) Age-Related Macular Degeneration

Conditions

Neovascular (Wet) Age-Related Macular Degeneration

Trial Timeline

Dec 9, 2021 โ†’ Jan 1, 2031

NCT ID
NCT05197270

About 4D-150 IVT + Aflibercept IVT

4D-150 IVT + Aflibercept IVT is a phase 1/2 stage product being developed by 4D Molecular Therapeutics for Neovascular (Wet) Age-Related Macular Degeneration. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05197270. Target conditions include Neovascular (Wet) Age-Related Macular Degeneration.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (2)

NCT IDPhaseStatus
NCT05930561Phase 2Active
NCT05197270Phase 1/2Recruiting

Competing Products

20 competing products in Neovascular (Wet) Age-Related Macular Degeneration

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
33
CLS-AX + AfliberceptClearside BiomedicalPhase 2
44
Eylea + ALT-L9AlteogenPhase 1
33
UBX1325 injection 50 ฮผL + EYLEAยฎ (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
44
DS-7080a + RanibizumabDaiichi SankyoPhase 1
33
Avacincaptad PegolAstellas PharmaPhase 1
33
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
52
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
52
KHK4951 + Aflibercept InjectionKyowa KirinPhase 2
52
Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab ControlAbbViePhase 3
77
Ranibizumab + Local Steroid + Topical SteroidAbbViePhase 2
52
LucentisNovartisPre-clinical
23
ranibizumabNovartisPhase 3
77
BrolucizumabNovartisPre-clinical
23
ranibizumabNovartisApproved
85
brolucizumab + ranibizumab + afliberceptNovartisPre-clinical
23
BeovuNovartisPre-clinical
23
RanibizumabNovartisPhase 3
77
RanibizumabNovartisApproved
85
Intraviteal Ranibizumab 0.5mgNovartisApproved
85

Other Products from 4D Molecular Therapeutics

4D-150 IVT (3E10 vg/eye) + EYLEAยฎ (aflibercept) Injection 2 mg (0.05mL)Phase 3
69
4D-150 IVT (3E10 vg/eye) + EYLEAยฎ (aflibercept) Injection 2 mg (0.05mL)Phase 3
69
4D-150 IVT + Aflibercept IVTPhase 2
44
4D-710Phase 2
44
4D-310Phase 1/2
33